Literature DB >> 9699521

Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry.

H J Blaheta1, B Schittek, H Breuninger, E Maczey, S Kroeber, K Sotlar, U Ellwanger, M H Thelen, G Rassner, B Bültmann, C Garbe.   

Abstract

The presence of regional lymph node metastases is one of the most significant prognostic factors for predicting survival in patients with clinical stage I or II cutaneous melanoma. For accurate staging of the primary tumor a sensitive technique is required to detect occult nodal micrometastases. This prospective diagnostic study was designed to evaluate the incidence of nodal micrometastases using nested reverse transcription-polymerase chain reaction (RT-PCR) for tyrosinase in comparison to immunohistochemical examination. Furthermore, the incidence of melanoma micrometastases detected by RT-PCR was analysed in correlation to major prognostic factors. A total of 466 regional lymph nodes from 79 patients with primary cutaneous melanoma (tumor thickness > 0.75 mm) were investigated. In 49 lymph nodes from 31 patients immunohistochemistry demonstrated melanoma metastases. Using tyrosinase RT-PCR, nodal micrometastases were detected in 136 lymph nodes from 52 patients including all lymph nodes positive by immunohistochemical examination. Out of the 417 lymph nodes negative by immunohistochemistry, 87 nodes (21%) were identified to express tyrosinase by the RT-PCR technique. Among the 48 patients negative by immunohistochemical assessment, 21 (44%) had nodal micrometastases (n = 40) using RT-PCR. All 68 lymph nodes from 46 non-melanoma patients serving as negative controls for tyrosinase RT-PCR were negative. The detection of melanocytic nodal micrometastases by tyrosinase RT-PCR is a highly specific method with a sensitivity significantly higher than that achieved by immunohistochemistry (p < 0.0001). Patients with nodal micrometastases identified exclusively by RT-PCR had significantly higher tumor thickness as compared to patients with negative results by RT-PCR (p < 0.01).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699521     DOI: 10.1002/(sici)1097-0215(19980821)79:4<318::aid-ijc3>3.0.co;2-y

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Sentinel lymph node: detection of micrometastases of melanoma in a molecular study.

Authors:  Valeria C Denninghoff; Andrea G Kahn; Jorge Falco; Hector P Curutchet; Boris Elsner
Journal:  Mol Diagn       Date:  2004

2.  The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).

Authors:  K S Clarkson; I C Sturdgess; A J Molyneux
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

Review 3.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

Review 4.  Molecular pathology of tumor metastasis. II. Molecular staging and differential diagnosis.

Authors:  József Tímár; Orsolya Csuka; Zsolt Orosz; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

5.  Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate.

Authors:  V Davids; S H Kidson; G S Hanekom
Journal:  Mol Pathol       Date:  2003-02

6.  Prognostic significance of melanoma differentiation and trans-differentiation.

Authors:  Nityanand Maddodi; Vijayasaradhi Setaluri
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

7.  Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes.

Authors:  A Calogero; H Timmer-Bosscha; H Schraffordt Koops; A T Tiebosch; N H Mulder; G A Hospers
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.